

Angivent[®] MR

Trimetazidine Hydrochloride BP

PRESENTATION

Angivent[®] MR Tablet: Each modified release tablet contains Trimetazidine Hydrochloride BP 35 mg.

DESCRIPTION

Mechanism of Action:

Trimetazidine Hydrochloride has been proven to exert antianginal properties due to its specific metabolic mechanism of action. Trimetazidine Hydrochloride reduces the metabolic damage caused during ischemia, by acting on a critical step in cardiac metabolism: fatty acid β -oxidation. This is made possible by selective inhibition of an enzyme of fatty acid β -oxidation: the long-chain 3-ketoacyl CoA thiolase (3-KAT). This inhibition results in reduction in fatty acid oxidation & stimulation of glucose oxidation.

Thus, the coupling of glycolysis with glucose oxidation is improved, and ATP production is further increased, while the deleterious consequences of acidosis and of Ca²⁺ overload are limited.

INDICATIONS

Long-term treatment of angina pectoris.

DOSAGE & ADMINISTRATION

One tablet at mealtimes in the morning and evening.

CONTRAINDICATIONS

Hypersensitivity to Trimetazidine Hydrochloride.

SIDE EFFECTS

Rare cases of gastrointestinal disorders.

USE IN PREGNANCY AND LACTATION

Pregnancy: Studies in animals have not demonstrated a teratogenic effect. However, in the absence of clinical data and for safety reasons, prescription should be avoided during pregnancy.

Breastfeeding: In the absence of data, breastfeeding is not recommended during treatment.

STORAGE CONDITION

Protect from light and moisture. Store below 30° C. Keep the medicine out of reach of children.

HOW SUPPLIED

Angivent[®] MR tablet: Each box contains 3x10 tablets in blister pack.

Manufactured by



SQUARE

PHARMACEUTICALS LTD.
BANGLADESH